Australians are facing a double blow, with soaring petrol prices already hitting wallets hard, and now there are growing concerns that the cost of essential medications could also skyrocket. The ongoing conflict in the Middle East, particularly the war in Iran, is creating significant logistical hurdles and supply chain disruptions that could lead to a spike in prescription prices.
Even a minor increase in the cost of medicines or a brief period of scarcity could have a significant impact on both the financial wellbeing and health of Australians.
Medical Supply Chains Under Strain
Pharmaceutical companies are currently working around the clock to reroute critical medical supplies. The blockade on the Strait of Hormuz, a vital trade artery, has forced some companies to shift from sea freight to air freight for medical supplies destined for Australia, ensuring they reach their destination despite the disruptions.
Furthermore, to circumvent potential closures of Middle Eastern airspace, which can happen with little warning, alternative flight paths are being utilised. This complex rerouting adds to the cost and complexity of getting medicines to Australia.
The Ripple Effect on Common Drugs
The impact of these geopolitical events extends to the very ingredients used to manufacture many everyday medicines. Crucial petroleum-based components, essential for the production of common drugs like paracetamol, ibuprofen, and antibiotics, could soon face shortages. Similarly, raw materials sourced from the Middle East, which are integral to the formulation of numerous medications, are also at risk of becoming scarce.
These compounding factors – shipping disruptions, air traffic rerouting, and ingredient shortages – are creating a perfect storm that could lead to manufacturing delays, medicine shortages, and ultimately, higher prices for consumers in Australia.
Expert Advice: Don’t Panic, But Be Aware
Despite the worrying developments, the Royal Australian College of General Practitioners (RACGP) president, Dr. Michael Wright, has urged the public to remain calm.
“If we do have a shortage, people shouldn’t panic because in most situations there will be an alternative,” Dr. Wright stated. He also highlighted the significant role of the Pharmaceutical Benefits Scheme (PBS). “And for most people, given that most medications are on the PBS, it shouldn’t make a difference to the price.”
However, for medications not covered by the PBS, price increases are a distinct possibility, though the extent of these hikes remains uncertain and contingent on the duration of the supply chain disruptions.
Medicines Australia has acknowledged the current shipping route disruptions, noting that delays have generally been limited to a few days. The organisation is closely monitoring the situation and confirmed that pharmaceutical companies have contingency plans in place.
“We would also encourage patients not to panic buy or stockpile medicines, as this can place unnecessary pressure on supply and impact access for others,” a statement from Medicines Australia advised.
A Pre-Existing Vulnerability
It’s important to note that Australia has been grappling with medicine shortages even before the current Middle Eastern conflict. The COVID-19 pandemic highlighted existing vulnerabilities in the nation’s pharmaceutical supply chain. Currently, there are almost 400 medicine shortages in Australia, with 37 classified as critical and over 90 anticipated shortages.
The war in the Middle East has the potential to exacerbate these existing issues, further complicating the already challenging task of getting medications to Australian shores.
The Reliance on Imports
The Therapeutic Goods Administration (TGA) plays a crucial role in monitoring medicine shortages and has previously fast-tracked alternative medicines during critical supply gaps. However, the stark reality is that Australia imports approximately 90 per cent of its medications and the majority of the raw ingredients used in their manufacture. This heavy reliance makes the prospect of extended supply issues particularly concerning.
Professor Mark Morgan, chair of the RACGP Expert Committee on Quality Care, expressed the anxieties of many. “Our patients are very concerned about the impact of medicines supply,” he said. “There are few things more concerning than potentially losing access to a medicine you have been advised to take for your health.”
Towards Greater Self-Sufficiency?
The current global supply shock underscores Australia’s vulnerability to international disruptions. Dr. Wright suggested a potential long-term solution: “One thing we probably could do more of is we could produce more medications locally, and that would be a way to get around some of our dependencies.”
Professor Morgan concurred, believing that a robust local pharmaceutical manufacturing industry could significantly mitigate the supply risks Australia currently faces.
In the United Kingdom, which also relies heavily on imported medicines, calls have been made for government intervention to prevent major shortages. Measures proposed include shorter prescription durations to deter stockpiling and legislation to ban the export of certain essential drugs.
However, Dr. Wright reiterated that Australia has not yet reached a point of requiring such drastic measures. “We certainly don’t have to panic or take sort of drastic action at this point.”
